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Drug treatment and/or implantable cardioverter deﬁbrillator (ICD) implantation are the most widely
accepted ﬁrst-line therapies for channelopathic patients who have recurrent syncope, sustained ven-
tricular tachycardia (VT), or documented ventricular ﬁbrillation (VF), or are survivors of cardiac arrest. In
recent years, there have been signiﬁcant advances in mapping techniques and ablation technology,
coupled with better understanding of the mechanisms of ventricular tachyarrhythmia in channelo-
pathies. Catheter ablation has provided important insights into the role of the Purkinje network and the
right ventricular outﬂow tract in the initiation and perpetuation of VT/VF, and has evolved as a promising
treatment modality for ventricular tachyarrhythmia even in channelopathies. When patients are exposed
to a high risk of sudden cardiac death or deterioration of their quality of life due to episodes of tachy-
cardia and frequent ICD discharges, catheter ablation may be an effective treatment option to reduce the
risk of sudden cardiac death and decrease the frequency of cardiac events. In this review, we summarize
the current understanding of catheter ablation for VT/VF in patients with channelopathies including
Brugada syndrome, idiopathic VF, long QT syndrome, and catecholaminergic polymorphic VT.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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A channelopathy (also termed a primary electrical disorder) is
deﬁned as an inherited syndrome caused by mutations in genes
encoding for ion channels, their subunits, or their associatedblished by Elsevier B.V. This is an
stitute of Clinical Medicine,
noudai, Tsukuba, Ibaraki 305-
3143.
(N. Murakoshi),proteins [1]. Drug therapy and implantable cardioverter deﬁ-
brillator (ICD) implantation are generally used as ﬁrst-line thera-
pies for the treatment and prevention of sudden cardiac death
(SCD) in channelopathy patients [1]. However, recent advances in
mapping techniques and ablation technology allow us to perform
ablation therapy more safely and effectively for the treatment of
ventricular tachycardia (VT) and ventricular ﬁbrillation (VF), even
in channelopathies. A recent consensus report recommended that
catheter ablation of VT or a triggering focus of VF should be con-
sidered as a class IIa indication in patients with VT/VF storm when
adequate operator experience is available, although, presumably,open access article under the CC BY-NC-ND license
N. Murakoshi, K. Aonuma / Journal of Arrhythmia 32 (2016) 404–410 405this recommendation also includes VT/VF in patients with struc-
tural heart disease [1]. According to the European Heart Rhythm
Association Survey, catheter ablation for tachyarrhythmia is cur-
rently undertaken in 5–10% of recurrent cases with channelo-
pathies such as Brugada syndrome (BrS) and long QT syndrome
(LQTS) [2]. However, the long-term effectiveness of catheter
ablation for VT/VF remains to be precisely elucidated as no ran-
domized data on the effect of catheter ablation on arrhythmic
events has been collected. In this article, we summarize the clin-
ical reports on catheter ablation for the treatment of VT/VF in
channelopathic patients in Table 1 and describe the current
understanding of this ﬁeld.2. Brugada syndrome
BrS is characterized by coved-type or saddleback-type ST-seg-
ment elevation in the right precordial leads of the standard elec-
trocardiogram (ECG) or high intercostal ECG. It is associated with
an increased risk of SCD due to VF [3]. Approximately 15–30% of
BrS cases are attributed to mutations in SCN5A, and a further 10–
20% of BrS cases are attributed to mutations in other genes [4,5].
ICD implantation is recommended in patients with a diagnosis of
BrS who are survivors of a cardiac arrest and/or have documented
VF or spontaneous sustained VT with or without syncope. Iso-
proterenol and quinidine are also useful for the treatment of
electrical storm in BrS patients. Experimental studies have shown
that heterogeneous loss of the action potential dome occurs at the
right ventricular (RV) epicardial sites, resulting in a marked dis-
persion of repolarization which underlies the development of local
re-excitation via a mechanism termed phase 2 reentry in BrS [6].
Phase 2 reentrant ventricular extrasystole can trigger polymorphic
VT/VF. Therefore, the elimination of trigger ventricular premature
contractions (VPCs) might suppress VT/VF.
Haïssaguerre et al. reported the electrophysiological properties
and effects of catheter ablation in three symptomatic patients with
BrS [7], with one patient exhibiting a familial SCN5A deletion
mutation (2850delT). Monomorphic VPCs originating from the RV
outﬂow tract (RVOT) were observed in all patients, with mono-
morphic VPCs with left bundle-branch block (LBBB) and superior
axis in one patient. RVOT triggers were eliminated by radio-
frequency (RF) energy applications at the earliest site (25 and
40 ms before QRS onset), and VF inducibility was modiﬁed after
ablation in two patients. In the third patient, RF energy application
could ablate the VPCs originating from the anterior RV Purkinje
network, thus rendered the VF non-inducible. During a mean
follow-up period of 776 months, there was no evidence of
recurrence of syncope, VF, or SCD in any of the patients.
Nademanee et al. reported nine symptomatic patients with BrS
who experienced VF and underwent electrophysiological study
and catheter ablation [8]. The patients exhibited abnormal epi-
cardial electrograms characterized by fragmented electrograms
with a relatively low voltage (o1 mV), prolonged duration, and
fractionated late potentials exclusively localized over the anterior
aspect of the RVOT epicardium. Catheter ablation over these
abnormal areas at the epicardial sites of the anterior aspect of the
RVOT rendered the VT/VF non-inducible in seven of nine patients
(78%) and normalized the Brugada ECG pattern in eight patients
(89%). After a mean follow-up of 2076 months, eight of nine
patients (89%) had no recurrence of VF episodes, and there were
no shocks from the ICD. Amiodarone was resumed at 100 mg daily
in only one patient with VF recurrence after ablation, and there
were no VT/VF recurrences up to 33 months after the ablation.
Thus, RVOT was suggested to be an important target for catheter
ablation, as an originating site of trigger VPCs and as an arrhyth-
mogenic substrate of VF in BrS [9–11].3. Idiopathic ventricular ﬁbrillation
Idiopathic ventricular ﬁbrillation (IVF) is generally diagnosed
by exclusion of apparent structural heart disease, identiﬁable
genetic syndromes, and any other potential causes of VF [12]. Thus,
IVF may not strictly be categorized as a channelopathy. The gold
standard treatment for either primary or secondary prevention of
SCD is the insertion of an ICD. Recent progress in understanding
the mechanism of IVF strongly suggests that the Purkinje network
[13–17] and the RVOT [15,18] play a pivotal role in both the
initiation and perpetuation of VF.
PVCs originating from the RVOT occasionally trigger VF
although these are generally considered to be benign. Noda et al
reported on 16 patients who showed spontaneous VF and/or
polymorphic VTs initiated by VPCs arising from the RVOT [17]. The
optimal ablation site was determined by the earliest local activa-
tion site during the spontaneous target VPC and/or by pace map-
ping. Eventually, catheter ablation with a mean of 974 RF energy
applications was successful in 13 of 16 patients and partially suc-
cessful in three patients. During programmed ventricular stimu-
lation after ablation, nonsustained polymorphic VT was induced in
two patients and VF in one patient who underwent ICD implan-
tation. During a mean-follow-up period of 54739 months, there
were no episodes of syncope, VF, or SCD (four patients received a
β-blocker).
The short-coupled variant of torsades de pointes (TdP) is
deﬁned as a syndrome in which VF is exhibited secondary to a
short-coupled VPC (with coupling interval o300 ms) without
obvious heart disease or QT prolongation [19]. The VPCs triggering
VF may arise from the Purkinje network rather than RVOT or the
working myocardium. Haïssaguerre et al summarized a cohort of
27 patients diagnosed as having IVF (without structural heart
disease, QT prolongation, or a Brugada-like ECG) who underwent
catheter ablation [15]. In this study, VPCs originated from the
Purkinje networks in 23 patients (LV septum in 10, anterior RV in
nine, both in four), and from the RVOT in four patients, and the
former had a shorter coupling interval initiating VF or poly-
morphic VT than the latter (280726 vs 355730 ms). The interval
from the Purkinje potential to the following myocardial activation
varied from 10 to 150 ms during premature beat but was 1175 ms
during sinus rhythm. After ablation for VPCs, 24 patients (89%)
without drug therapy had no VF recurrence during a 24728
months follow-up period.
The long-term prognosis of patients with IVF after catheter
ablation was reported in a multicenter study [20]. VPCs originated
from the right (n¼16), the left (n¼14), or both (n¼3) Purkinje
systems, and from the myocardium (n¼5) (including the RVOT
[n¼4]). After ablation, seven (18%) of the 38 patients (21 men, age
42713 years) experienced VF recurrence during a median post-
procedural follow-up period of 63 months. Five of these seven
patients underwent repeat ablation and had no subsequent
recurrence of VF or documented VPCs for 28 months. The number
of signiﬁcant events (conﬁrmed VF or aborted SCD) was reduced
from 4 (interquartile range 3–9) before ablation to 0 (interquartile
range 0–4) after ablation (po0.01). Taken together, short-coupled
VPCs triggering VF originate predominantly from the Purkinje
system and the RVOT, and catheter ablation for the triggers is
feasible and is associated with long-term freedom from VF recur-
rence in patients with IVF.
Early repolarization (ER) is characterized by elevation of the QRS-
ST junction (J point) and QRS notching or slurring (J wave) in multiple
leads, especially the inferior and/or left precordial leads. Although this
ﬁnding has been considered to be a benign ECG manifestation, Haïs-
saguerre et al reported that the ER pattern was found in 31% (64/206)
of IVF patients compared to 5% (21/412) of matched control subjects
[21]. An ER pattern in the inferior or inferolateral leads has been
Table 1
Summary of case reports of catheter ablation for ventricular tachyarrhythmias in patients with channelopathies.
Diagnosis Authors n Age/Sex Symptoms Genes VPC morphology/origin Electrophysiology Ablation Outcome Ref
BrS Haïssaguerre et al. 3 3977,
2 males,
1 female
Syncope, PVT, VF SCN5A mutation
(2850delT) in 1
#1 RVOT in 2 pts #2 LBBB
superior axis/anterior; RV Pur-
kinje network in 1 pt.
#1 CI: 340720, 408715 ms #2
CI: 278729 ms
Successful ABL for
VPCs
No rec (776 mo) #7
Darmon et al. 1 18, male Frequent VF, PVT Not described Posterior RVOT - Successful ABL for
VPCs and AT
No rec (6 mo) #9
Nakagawa et al. 1 41, male VF storm Not described LBBB inferior axis/RVOT CI: 390–450 ms Successful ABL for
VPCs
No VF rec (29 mo) #10
Nademanee et al. 9 38, all males All had out-of-hospi-
tal cardiac arrests.
Not performed Not described Low voltage (0.9470.79 mV),
prolonged duration (132748 ms),
and fractionated late potentials
(96747 ms beyond QRS complex)
in the anterior RVOT epicardium.
Successful ABL for
substrate in the ante-
rior of RVOT
epicardium.
Only 1 of 9 pts had VF
rec (2079 mo)
#8
Sunsaneewitayakul
et al.
10 36.5, all
male
4 had frequent VF or
storm; 6 had syncope
or VF episodes.
Not performed Posterolateral RV in 1 pt. No
VPCs in 9 pts.
Late activation zone (where elec-
trical activity was recorded by
isopotential map within J point to
J point þ 60 ms) was observed in
all patients.
Successful ABL for
substrate at late acti-
vation zone of RVOT.
1 pt. had CRBBB dur-
ing procedure.
Modiﬁed Brugada ECG
in 3 of 4 pts (75%) and
no VF storm in 4
(100%) (12–30 mo).
#11
IVF Aizawa et al. 1 13, male Convulsion, VF Not described #1 RBBB/posterolateral LV #2
LBBB superior axis/RV
Fractionated activities were recor-
ded at posterolateral LV, J wave
(þ).
ABL for VPCs VF rec 1.5 mo after 1st
ABL, but no rec 3 mo
after 2nd ABL.
#23
Ashida et al. 1 18, female Syncope, TdP Not described LBBB inferior axis/RVOT QT/QTc 0.39/0.3 ms. CI: 380 ms, J
wave (-)
Successful ABL for
VPC
No TdP and syncope
(3 yr)
#13
Takatsuki et al. 1 62, male Syncope, VF Not described RVOT CI: 320–330 ms, J wave (-) Successful ABL for
VPC
no VF rec (20 mo) #14
Haïssaguerre et al. 27 41714, 13
males, 14
females
VF (23 during daily
activity and 4 during
sleep); LQT and Bru-
gada ECG were
excluded.
12 pts had no
mutations in SCN5A
and KCNH2
RBBB 10, LBBB 13, both 4. #1
Purkinje system in 23 (LV sep-
tum in 10, anterior RV in 9, both
in 4) #2 RVOT in 4.
CI: 20–160 ms (75742) #1 The
interval from the Purkinje poten-
tial to the following myocardial
activation: 10–150 ms
(38728 ms) during premature
beats, 1175 ms during sinus
rhythm.
Successful ABL for
VPCs
24 pts (89%) had no VF
rec without drug
(24728 mo). 3 pts
had late rec.
#15
Betts et al. 1 32, male Syncope, VF storm Not described LBBB/RVOT free wall CI: 260–300 ms Successful ABL for
VPC
No VF rec (11 mo) #16
Nogami et al. 1 54, male Syncope, VF No mutation in
SCN5A
#1 RBBB inferior axis/LV sep-
tum #2 RBBB northwest axis/LV
#1 CI: 280 ms #2 CI: 260 ms dia-
stolic Purkinje potential and pre-
systolic Purkinje potential were
recorded from LV during PVT.
Successful ABL for
VPC but isolated VPC
was inducible.
No VF and syncope rec
(4 yr) without drugs.
#18
Noda et al. 16 39710,
7 males,
9 females
Syncope, VF, poly-
morphic VT (VF in
5 pts)
Not described LBBB 16/RVOT septum 13, free
wall 3
CI: 409762 ms, CL: 245728 ms,
polymorphic changes of the QRS
complex during rapid pacing in
2 pts.
Successful ABL for
VPCs in 13, partially
successful in 3.
No syncope, VF, SCDs
(54739 months) (4
patients received a β-
blocker).
#17
Latcu DG et al 1 57, male Aborted SCD, recur-
rent VF
Not described RBBB/inferoseptal LV near pos-
terior hemibranch (small num-
ber of VPCs)
J wave in inferior leads, no scar. Successful ABL, J wave
disappeared.
No VF rec and no
occurrence of J wave
(2 months).
#24
LQTS Haïssaguerre et al 4 3778,
2 males,
2 females
Syncope, PVT, VF No mutation in
KCNQ1, KCNH2, and
SCN5A
#1 LBBB inferior axis /RVOT in
1 pt. #2 RBBB superior axis/
Purkinje in LV in 1 pt. #3 Poly-
morphic, repetitive (bidirec-
tional) with a positive mor-
phology in V1/ Purkinje in LV in
2 pts.
#1, #2 CI: 503729 ms. #3 PVT
cycle length: 280–420 ms lasting
3 to 45 beats, Purkinje potential
proceeded VPCs/repetitive beats.
Successful ABL for
VPCs
No VF rec
(24720 mo), 1 pt had
a rec of VPCs.
#7
Srivathsan et al 1 39, female VF Not described Purkinje in midposterior septal
LV
CI: 340 ms Purkinje potential pre-
ceded VPCs by 30 ms.
Successful ABL for
VPCs
No rec (6 mo) #28
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N. Murakoshi, K. Aonuma / Journal of Arrhythmia 32 (2016) 404–410 407reported to be associated with an increased risk for life-threatening
arrhythmias, termed ER syndrome. ER has also been reported to
coexist with other arrhythmogenic disorders such as BrS, short QT
syndrome, and arrhythmogenic right ventricular cardiomyopathy;
therefore, ER may be viewed as one of many arrhythmogenic factors
that is rarely solely responsible for clinical events [22]. Aizawa et al.
ﬁrst reported a patient with ER-like QRS notching and VF without any
apparent cause, which were suppressed by catheter ablation for the
VPCs triggering the VF [23]. Recently, a case was reported of a patient
with recurrent VF storm and inferoposterior ER in whom catheter
ablation guided by pace mapping of the triggering VPCs successfully
abolished the clinical event and caused the ER to disappear [24].4. Long QT syndrome
LQTS is characterized by prolonged ventricular repolarization and
susceptibility to syncope and SCD through VT (TdP), which can
deteriorate into VF [25]. A clinical diagnosis is made from a combi-
nation of clinical history, family history, and 12-lead ECG, which
typically reveals a heart rate-corrected QT interval (QT interval divided
by the square root of the RR interval in seconds¼QTc) of greater than
0.46 s in women and 0.45 s in men [25].
LQTS is most commonly inherited in an autosomal dominant
fashion and has been associated with mutations in 15 genes.
Among these, more than 75% of the mutations in congenital LQTS
were of the KCNQ1 (LQT1), KCNH2 (LQT2), or SCN5A (LQT3) genes
[26]. β-blocker therapy is associated with a 50% reduction in risk of
cardiac events, and mexiletine is effective in LQT3 patients [27].
ICD implantation is recommended for patients with resuscitated
cardiac arrest/VF or recurrent syncope who are on β-blockers.
Several studies have suggested that early afterdepolarizations
arising from the Purkinje network and/or myocardial ﬁbers are the
primary triggering beats in TdP [7,28–31]. For example, Haïssa-
guerre et al. reported four symptomatic LQTS patients diagnosed
on the basis of a corrected QT interval of 4 460 ms who under-
went catheter ablation [7]. In one patient, VPCs originating from
the RVOT were ablated by RF energy applications. In three
patients, VPCs originated from the left Purkinje system and were
eliminated by ablation at multiple sites. During a mean follow-up
period of 24720 months, there was no recurrence of syncope, VF,
or SCD in any patient, although one patient with LQTS was
maintained on a β-blocker, and another had a late recurrence of
VPCs. The authors concluded that the triggers from the Purkinje
network or the RVOT play a crucial role in initiating TdP or VF in
LQTS, and these can be eliminated by focal ablation. Other groups
also reported that VPCs originating from the RV free wall and RV
inferoseptal wall could trigger VT/VF and could be eliminated by
focal ablation [30,31].5. Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic VT (CPVT) is an inherited
arrhythmogenic disorder characterized by polymorphic VT
induced by physical or emotional stress with no detectable mor-
phological abnormalities in the heart [32]. To date, ﬁve genes,
cardiac ryanodine type 2 receptor (RYR2), calsequestrin 2 (CASQ2),
KCNJ2 (which encodes Kir2.1), calmodulin 1 (CALM1), and triadin
(TRDN), have been identiﬁed as being involved in CPVT [33].
Typical arrhythmias include bidirectional VT and polymorphic VT
that can degenerate into VF and thus SCD. β-blockers and addi-
tional administration of ﬂecainide or verapamil have been repor-
ted to be effective for the prevention of VT/VF [34]. An ICD is
considered the deﬁnitive therapy for the prevention of SCD,
although failure of the ICD to prevent SCD has been reported in
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Fig. 1. Twelve-lead ECG recording during epinephrine stress test. Continuous intravenous infusion of epinephrine was started at a rate of 0.025 μg/kg per min, and the QT
interval did not change. At a rate of 0.1 μg/kg per min, VPC #1 (right bundle branch block conﬁguration and superior axis), VPC #2 (right bundle branch block conﬁguration
and inferior axis; the same as that induced in treadmill exercise testing), and VPC #3 (left bundle branch block conﬁguration and inferior axis) were induced. Subsequently,
VPC #1 following VPC #2 suddenly induced ventricular ﬁbrillation, which was successfully terminated with electric shock. (Cited from [37]. With permission from Lippincott
Williams & Wilkins.).
Fig. 2. Electrophysiological study and catheter ablation for catecholaminergic polymorphic ventricular tachycardia. (A) Activation mapping and pace mapping for VPC #1. A
Purkinje potential was recorded from the left ventricular inferoseptum and preceded the QRS onset by 18 ms (arrowheads). The unipolar electrogram recorded from the
distal electrode showed a QS pattern. Perfect pace mapping was obtained at this site. (B) Activation mapping and pace mapping for VPC #2. A local bipolar electrogram
recorded from the LCC showed a discrete prepotential that preceded the QRS onset by 65 ms and was associated with a QS pattern in the unipolar electrogram. Perfect pace
mapping was obtained at this site. ABL, ablation catheter; Bi., bipolar; CS, coronary sinus; His, His bundle; RVa, right ventricular apex; LCC, left coronary cusp; SR, sinus
rhythm; Uni., unipolar; VPC, ventricular premature contraction. (Cited from Ref. [37]. With permission from Lippincott Williams & Wilkins.).
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cholamine release, resulting in an electric storm [35].
Cerrone et al. reported that the mechanism of CPVT was due to
delayed afterdepolarization‐induced triggered activity in a focal
Purkinje network in a knock-in (RyR2) mouse [36]. In addition,
chemical ablation of the RV endocardial cavity with Lugol's solu-
tion, which selectively destroys the Purkinje network, could con-
vert bidirectional VT into monomorphic VT in a CPVT model of
anesthetized mice. Therefore, the Purkinje network is considered
to be a critical contributor to arrhythmogenic triggers in CPVT and
may be a promising therapeutic target for catheter ablation.
Our group presented the ﬁrst case report of the successful
catheter ablation of bidirectional VPCs triggering VF in patients
with CPVT [37]. This case was of a 38-year-old woman who had
often experienced syncope since childhood. The patient's daughteralso had similar episodes of syncope and developed VF during
treadmill exercise testing, which was successfully deﬁbrillated
with an electric shock. Witnessing this situation, the patient also
lost consciousness, with documented VF which was converted to
sinus rhythm by cardiopulmonary resuscitation. There were no
signiﬁcant abnormalities in her resting 12-lead ECG, echocardio-
graphy, or coronary angiography. Genetic analysis revealed that
she and her daughter had same missense mutation (c.1259 G4A,
p.R420Q) in RyR2, and both were diagnosed as having CPVT.
During the patient's epinephrine stress test (Fig. 1), multifocal
VPCs (VPC #1, RBBB, and superior axis; VPC #2, RBBB, and inferior
axis, the same VPC conﬁguration as that induced during the
treadmill exercise testing; and VPC #3, LBBB, and inferior axis)
appeared, and VPC #1 following VPC #2 subsequently induced VF.
We performed catheter ablation targeting the catecholamine-
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inferoseptal area near the posteromedial papillary muscle, where a
presystolic Purkinje potential preceded VPC #1 by 18 ms. RF
energy application to this site accelerated the VPCs, and additional
applications around the target site subsequently eliminated VPC
#1. After the procedure, VPC #2 continued to occur, and a local
bipolar electrogram recorded on the left coronary cusp showed a
discrete prepotential that preceded the onset of VPC #2 by 65 ms.
RF energy application to the left coronary cusp abolished VPC #2.
After ablation at both sites, neither the VPCs nor VF was inducible,
even with an infusion of epinephrine at up to 1.2 g/kg per min. The
patient underwent ICD implantation and was discharged from the
hospital on bisoprolol. During a 16-month follow-up after ablation,
no episodes of syncope or ICD therapy occurred. Thus, catheter
ablation of the bidirectional VPCs triggering VF may become an
adjunctive therapeutic option for CPVT.
In addition to ventricular tachyarrhythmia, patients with CPVT are
likely to be complicated with supraventricular tachyarrhythmia such
as atrial ﬁbrillation and supraventricular tachycardia (SVT). Typically,
the onset of supraventricular tachyarrhythmia is observed at lower
heart rates than ventricular arrhythmia in patients with CPVT.
Supraventricular tachyarrhythmia may be a precursor to VT and may
be a cause of frequent and inappropriate shocks from an ICD asso-
ciated with SVT with a rapid ventricular response. Therefore, catheter
ablation targeting SVT may be effective in reducing the number of
cardiac events in patients with CPVT.6. Conclusions
VT/VF in patients with channelopathies can be suppressed by
elimination of the triggered VPCs originating from the Purkinje net-
work and/or around the RVOT, and/or by substrate modiﬁcation of
possible re-entry circuits. Further studies are required to evaluate the
precise mechanisms and long-term prognosis of channelopathies.Conﬂict of Interest
All authors declare no conﬂict of interest related to this study.Acknowledgements
We wish to express our gratitude to Mr George Powell for his
editorial assistance with the manuscript.
This work was supported by a Grant-in-Aid from the Ministry
of Health, Labour and Welfare, and Health and Labour Sciences
Research Grants, Japan. Research on Health Services: Intractable
Diseases Conquest Research: H21-Nanchi-Ippan-059, Intractable
Diseases Conquest Research: H22-Nanchi-Ippan-144, Intractable
Diseases Conquest Research: H23-Nanchi-Ippan-144, and Intract-
able Diseases Conquest Research: H24-Nanchi-Ippan-033.References
[1] Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus
statement on the diagnosis and management of patients with inherited pri-
mary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS
in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm
2013;10:1932–63.
[2] Hocini M, Pison L, Proclemer A, et al. Diagnosis and management of patients
with inherited arrhythmia syndromes in Europe: results of the European
Heart Rhythm Association Survey. Europace 2014;16:600–3.
[3] Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the
second consensus conference: endorsed by the Heart Rhythm Society and the
European Heart Rhythm Association. Circulation 2005;111:659–70.[4] Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of Brugada
syndrome: a mutation update. Hum Mutat 2009;30:1256–66.
[5] Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of
mutations in the SCN5A-encoded cardiac sodium channel in patients referred
for Brugada syndrome genetic testing. Heart Rhythm 2010;7:33–46.
[6] Morita H, Zipes DP, Morita ST, et al. Epicardial ablation eliminates ventricular
arrhythmias in an experimental model of Brugada syndrome. Heart Rhythm
2009;6:665–71.
[7] Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of
ventricular ﬁbrillation associated with long-QT and Brugada syndromes. Cir-
culation 2003;108:925–8.
[8] Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular
ﬁbrillation episodes in Brugada syndrome by catheter ablation over the
anterior right ventricular outﬂow tract epicardium. Circulation
2011;123:1270–9.
[9] Darmon JP, Bettouche S, Deswardt P, et al. Radiofrequency ablation of ven-
tricular ﬁbrillation and multiple right and left atrial tachycardia in a patient
with Brugada syndrome. J Interv Card Electrophysiol 2004;11:205–9.
[10] Nakagawa E, Takagi M, Tatsumi H, et al. Successful radiofrequency catheter
ablation for electrical storm of ventricular ﬁbrillation in a patient with Bru-
gada syndrome. Circ J 2008;72:1025–9.
[11] Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial mapping and
catheter ablation for ventricular ﬁbrillation prevention in Brugada syndrome. J
Cardiovasc Electrophysiol 2012;23(Suppl 1):S10–6.
[12] Weerasooriya R, Hsu LF, Scavee C, et al. Catheter ablation of ventricular
ﬁbrillation in structurally normal hearts targeting the RVOT and Purkinje
ectopy. Herz 2003;28:598–606.
[13] Ashida K, Kaji Y, Sasaki Y. Abolition of Torsade de Pointes after radiofrequency
catheter ablation at right ventricular outﬂow tract. Int J Cardiol 1997;59:171–5.
[14] Takatsuki S, Mitamura H, Ogawa S. Catheter ablation of a monofocal pre-
mature ventricular complex triggering idiopathic ventricular ﬁbrillation. Heart
2001;86:E3.
[15] Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic
ventricular ﬁbrillation. Circulation 2002;106:962–7.
[16] Betts TR, Yue A, Roberts PR, et al. Radiofrequency ablation of idiopathic
ventricular ﬁbrillation guided by noncontact mapping. J Cardiovasc Electro-
physiol 2004;15:957–9.
[17] Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular
ﬁbrillation and polymorphic ventricular tachycardia initiated by premature
extrasystoles originating from the right ventricular outﬂow tract. J Am Coll
Cardiol 2005;46:1288–94.
[18] Nogami A, Sugiyasu A, Kubota S, et al. Mapping and ablation of idiopathic
ventricular ﬁbrillation from the Purkinje system. Heart Rhythm 2005;2:646–9.
[19] Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de
pointes. A new electrocardiographic entity in the spectrum of idiopathic
ventricular tachyarrhythmias. Circulation 1994;89:206–15.
[20] Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ven-
tricular ﬁbrillation ablation: a multicenter study. J Am Coll Cardiol
2009;54:522–8.
[21] Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated
with early repolarization. N Engl J Med 2008;358:2016–23.
[22] Obeyesekere MN, Klein GJ, Nattel S, et al. A clinical approach to early repo-
larization. Circulation 2013;127:1620–9.
[23] Aizawa Y, Tamura M, Chinushi M, et al. An attempt at electrical catheter
ablation of the arrhythmogenic area in idiopathic ventricular ﬁbrillation. Am
Heart J 1992;123:257–60.
[24] Latcu DG, Bun SS, Zarqane N, et al. Ablation of left ventricular substrate in
early repolarization syndrome. J Cardiovasc Electrophysiol 2015.
[25] Skinner JR, Group CCGW. Guidelines for the diagnosis and management of
familial long QT syndrome. Heart Lung Circ 2007;16:22–4.
[26] Mahida S, Hogarth AJ, Cowan C, et al. Genetics of congenital and drug-
induced long QT syndromes: current evidence and future research perspec-
tives. J Intervent Card Electrophysiol 2013;37:9–19.
[27] Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac
arrest and sudden cardiac death in children with the congenital long-QT
syndrome. Circulation 2008;117:2184–91.
[28] Srivathsan K, Gami AS, Ackerman MJ, et al. Treatment of ventricular ﬁbrilla-
tion in a patient with prior diagnosis of long QT syndrome: Importance of
precise electrophysiologic diagnosis to successfully ablate the trigger. Heart
Rhythm 2007;4:1090–3.
[29] Sanchez-Munoz JJ, Garcuia-Alberola A, Martinez-Sanchez J, et al. Ablation of
premature ventricular complexes triggering ventricular ﬁbrillation in a patient
with long QT syndrome. Indian Pacing Electrophysiol J 2011;11:81–3.
[30] Cheng Z, Gao P, Cheng K, et al. Elimination of fatal arrhythmias through
ablation of triggering premature ventricular contraction in type 3 long QT
syndrome. Ann Noninvasive Electrocardiol 2012;17:394–7.
[31] Yap J, Tan VH, Hsu LF, et al. Catheter ablation of ventricular ﬁbrillation storm
in a long QT syndrome genotype carrier with normal QT interval. Singapore
Med J 2013;54:e1–4.
[32] Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ven-
tricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation
1995;91:1512–9.
[33] Schwartz PJ, Ackerman MJ, George Jr. AL, et al. Impact of genetics on the
clinical management of channelopathies. J Am Coll Cardiol 2013;62:169–80.
N. Murakoshi, K. Aonuma / Journal of Arrhythmia 32 (2016) 404–410410[34] Watanabe H, Knollmann BC. Mechanism underlying catecholaminergic poly-
morphic ventricular tachycardia and approaches to therapy. J Electrocardiol
2011;44:650–5.
[35] Mohamed U, Gollob MH, Gow RM, et al. Sudden cardiac death despite an
implantable cardioverter-deﬁbrillator in a young female with catecholami-
nergic ventricular tachycardia. Heart Rhythm 2006;3:1486–9.
[36] Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic mechanisms in
a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Circ Res 2007;101:1039–48.[37] Kaneshiro T, Naruse Y, Nogami A, et al. Successful catheter ablation of
bidirectional ventricular premature contractions triggering ventricular ﬁbril-
lation in catecholaminergic polymorphic ventricular tachycardia with RyR2
mutation. Circ Arrhythm Electrophysiol 2012;5:e14–7.
